SBP Group Eyes Innovation as It Shifts Beyond Generics (opens original article in a new tab)

SBP Group is transitioning from a generics-focused model to drug development and innovation in China's healthcare sector.

• SBP Group plans to shift from generics to drug development
• SBP Group CEO Eric Tse discusses China's healthcare sector outlook
• SBP Group aims to focus on innovation